{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:14:33Z","timestamp":1791220473254,"version":"4.1.0"},"reference-count":184,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"University of Texas MD Anderson Cancer Center Melanoma Moon Shots Program"},{"name":"Robert and Lynne Grossman Family Foundation"},{"name":"Michael and Patricia Booker Melanoma Research Endowment"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA009599"],"award-info":[{"award-number":["T32 CA009599"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The incidence of melanoma in the United States has been increasing over the past several decades. Prognosis largely depends on disease stage, with 5-year melanoma-specific survival ranging from as high as 99% in patients with stage I disease to less than 10% for some patients with stage IV (distant metastatic) disease. Fortunately, in the last 5\u201310\u2009years, there have been remarkable treatment advances for patients with high-risk resectable melanoma, including approval of targeted and immune checkpoint blockade therapies. In addition, results of recent clinical trials have confirmed the importance of sentinel lymph node biopsy and continue to refine the approach to regional lymph node basin management. Lastly, the melanoma staging system was revised in the eighth edition AJCC Cancer Staging Manual, which was implemented on January 1, 2018. Here we discuss these changes and the clinicopathological features that confer high risk for locoregional and distant disease relapse and poor survival. Implications regarding the management of melanoma in the metastatic and adjuvant settings are discussed, as are future directions for neoadjuvant therapies.<\/jats:p>","DOI":"10.1093\/jnci\/djaa012","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T12:08:57Z","timestamp":1581422937000},"page":"875-885","source":"Crossref","is-referenced-by-count":28,"title":["Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma"],"prefix":"10.1093","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-8484","authenticated-orcid":false,"given":"Emily Z","family":"Keung","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E","family":"Gershenwald","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"issue":"6","key":"2020101314045151500_djaa012-B1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3322\/caac.21352","article-title":"State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now","volume":"66","author":"Tripp","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2020101314045151500_djaa012-B2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1245\/s10434-018-6379-8","article-title":"The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies","volume":"25","author":"Keung","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"2020101314045151500_djaa012-B3","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"9992","key":"2020101314045151500_djaa012-B4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2020101314045151500_djaa012-B5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2020101314045151500_djaa012-B6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2020101314045151500_djaa012-B7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2020101314045151500_djaa012-B8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2020101314045151500_djaa012-B9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"2020101314045151500_djaa012-B10","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"2020101314045151500_djaa012-B11","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2020101314045151500_djaa012-B12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline update","volume":"36","author":"Wong","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020101314045151500_djaa012-B13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"2020101314045151500_djaa012-B14","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"2020101314045151500_djaa012-B15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/978-3-319-40618-3_47","volume-title":"AJCC Cancer Staging Manual","author":"Gershenwald","year":"2017","edition":"8th ed"},{"issue":"36","key":"2020101314045151500_djaa012-B16","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2020101314045151500_djaa012-B18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","article-title":"Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma","volume":"172","author":"Breslow","year":"1970","journal-title":"Ann Surg"},{"issue":"9","key":"2020101314045151500_djaa012-B19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.2006.08.1463","article-title":"Identification of high-risk patients among those diagnosed with thin cutaneous melanomas","volume":"25","author":"Gimotty","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000658-197812000-00004","article-title":"A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark\u2019s and Breslow\u2019s staging methods","volume":"188","author":"Balch","year":"1978","journal-title":"Ann Surg"},{"issue":"13","key":"2020101314045151500_djaa012-B21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2011.38.8561","article-title":"Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020101314045151500_djaa012-B22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1245\/s10434-017-6325-1","article-title":"Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors","volume":"25","author":"Lo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"2020101314045151500_djaa012-B23","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020101314045151500_djaa012-B24","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/1097-0142(19800615)45:12<3012::AID-CNCR2820451223>3.0.CO;2-O","article-title":"The prognostic significance of ulceration of cutaneous melanoma","volume":"45","author":"Balch","year":"1980","journal-title":"Cancer"},{"issue":"4","key":"2020101314045151500_djaa012-B25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2559.1982.tb02737.x","article-title":"Ulceration and prognosis in cutaneous malignant melanoma","volume":"6","author":"McGovern","year":"1982","journal-title":"Histopathology"},{"issue":"5","key":"2020101314045151500_djaa012-B26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1245\/ASO.2003.09.016","article-title":"Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients","volume":"10","author":"Rousseau","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/SLA.0b013e31824c4b0b","article-title":"Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma","volume":"255","author":"In\u2019t Hout","year":"2012","journal-title":"Ann Surg"},{"issue":"3","key":"2020101314045151500_djaa012-B28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00000658-198103000-00023","article-title":"A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II)","volume":"193","author":"Balch","year":"1981","journal-title":"Ann Surg"},{"issue":"14","key":"2020101314045151500_djaa012-B29","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","article-title":"Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases","volume":"28","author":"Balch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B30","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1245\/s10434-012-2265-y","article-title":"Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma","volume":"19","author":"Murali","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2020101314045151500_djaa012-B31","volume-title":"AJCC Cancer Staging Manual","author":"Balch","year":"2002","edition":"6th ed"},{"issue":"6","key":"2020101314045151500_djaa012-B32","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.22511","article-title":"Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed?","volume":"109","author":"Lasithiotakis","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"2020101314045151500_djaa012-B33","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1245\/s10434-006-9267-6","article-title":"Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes","volume":"14","author":"Zogakis","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2020101314045151500_djaa012-B34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.0303-6987.2005.00310.x","article-title":"The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma","volume":"32","author":"Barnhill","year":"2005","journal-title":"J Cutan Pathol"},{"issue":"4","key":"2020101314045151500_djaa012-B35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1245\/ASO.2004.02.910","article-title":"The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma","volume":"11","author":"Busam","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2020101314045151500_djaa012-B36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1158\/1078-0432.CCR-16-2126","article-title":"Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: a retrospective review of 100 cases","volume":"23","author":"Nagarajan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020101314045151500_djaa012-B37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2016.08.066","article-title":"Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: a multi-institutional study of 1524 cases","volume":"76","author":"Mandal\u00e0","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"2020101314045151500_djaa012-B38","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","article-title":"Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database","volume":"29","author":"Thompson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B39","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/cncr.11196","article-title":"Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center","volume":"97","author":"Azzola","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"2020101314045151500_djaa012-B40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.6004\/jnccn.2009.0023","article-title":"Role of sentinel lymph node biopsy in patients with thin melanoma","volume":"7","author":"Andtbacka","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2020101314045151500_djaa012-B41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2015.09.014","article-title":"A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas","volume":"74","author":"Wat","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2020101314045151500_djaa012-B42"},{"key":"2020101314045151500_djaa012-B43","first-page":"383","article-title":"Malignant melanoma. A multivariate analysis of prognostic factors","volume":"24(pt 1):","author":"Vollmer","year":"1989","journal-title":"Pathol Annu"},{"issue":"3","key":"2020101314045151500_djaa012-B44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1997.15.3.1039","article-title":"Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system","volume":"15","author":"Buzaid","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020101314045151500_djaa012-B45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10434-000-0087-9","article-title":"Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial","volume":"7","author":"Balch","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2020101314045151500_djaa012-B46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ijc.2910260206","article-title":"Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma","volume":"26","author":"Prade","year":"1980","journal-title":"Int J Cancer"},{"issue":"1","key":"2020101314045151500_djaa012-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0046-8177(77)80061-0","article-title":"Problems in the measurement of tumor thickness and level of invasion in cutaneous melanoma","volume":"8","author":"Breslow","year":"1977","journal-title":"Hum Pathol"},{"issue":"3","key":"2020101314045151500_djaa012-B48","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res"},{"key":"2020101314045151500_djaa012-B49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-62703-727-3_16","article-title":"Tumor-infiltrating lymphocytes and their significance in melanoma prognosis","volume":"1102","author":"Schatton","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"7","key":"2020101314045151500_djaa012-B50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2006.08.9755","article-title":"Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma","volume":"25","author":"Taylor","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"2020101314045151500_djaa012-B51","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020101314045151500_djaa012-B52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjd.13171","article-title":"Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study","volume":"172","author":"Eriksson","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7","key":"2020101314045151500_djaa012-B53","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/PAS.0000000000000848","article-title":"A novel numerical scoring system for melanoma tumor-infiltrating lymphocytes has better prognostic value than standard scoring","volume":"41","author":"Saldanha","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2020101314045151500_djaa012-B54","doi-asserted-by":"crossref","first-page":"e0148160","DOI":"10.1371\/journal.pone.0148160","article-title":"Absence of tumor-infiltrating lymphocyte Is a reproducible predictive factor for sentinel lymph node metastasis: a multicenter database study by the Brazilian melanoma group","volume":"11","author":"Duprat","year":"2016","journal-title":"PLoS One"},{"issue":"21","key":"2020101314045151500_djaa012-B55","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020101314045151500_djaa012-B56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CMR.0000000000000164","article-title":"Tumor-infiltrating lymphocytes predict cutaneous melanoma survival","volume":"25","author":"Fortes","year":"2015","journal-title":"Melanoma Res"},{"issue":"9","key":"2020101314045151500_djaa012-B57","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archderm.137.9.1169","article-title":"Vascular involvement in the prognosis of primary cutaneous melanoma","volume":"137","author":"Kashani-Sabet","year":"2001","journal-title":"Arch Dermatol"},{"issue":"3","key":"2020101314045151500_djaa012-B58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00008390-200506000-00005","article-title":"Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis","volume":"15","author":"Nagore","year":"2005","journal-title":"Melanoma Res"},{"issue":"11","key":"2020101314045151500_djaa012-B59","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/hed.23801","article-title":"Lymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neck","volume":"37","author":"Pasquali","year":"2015","journal-title":"Head Neck"},{"issue":"4","key":"2020101314045151500_djaa012-B60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/modpathol.2011.182","article-title":"Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma","volume":"25","author":"Storr","year":"2012","journal-title":"Mod Pathol"},{"issue":"6","key":"2020101314045151500_djaa012-B61","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1211::AID-CNCR7>3.0.CO;2-C","article-title":"Independent prognostic importance of vascular invasion in nodular melanomas","volume":"78","author":"Straume","year":"1996","journal-title":"Cancer"},{"issue":"16","key":"2020101314045151500_djaa012-B62","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10434-000-0469-z","article-title":"Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience","volume":"7","author":"Cascinelli","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B64","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","article-title":"Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma","volume":"16","author":"Gershenwald","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0094-1298(20)32733-4","article-title":"Clinical classification and staging","volume":"27","author":"Gershenwald","year":"2000","journal-title":"Clin Plast Surg"},{"issue":"5","key":"2020101314045151500_djaa012-B66","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1245\/s10434-016-5723-0","article-title":"Extranodal spread is associated with recurrence and poor survival in stage III cutaneous melanoma patients","volume":"24","author":"Crookes","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2020101314045151500_djaa012-B67","first-page":"175","article-title":"Regional non-nodal metastases of cutaneous melanoma","volume":"12","author":"Cascinelli","year":"1986","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2020101314045151500_djaa012-B68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00000658-198107000-00019","article-title":"Malignant melanoma: prognostic significance of \u201cmicroscopic satellites\u201d in the reticular dermis and subcutaneous fat","volume":"194","author":"Day","year":"1981","journal-title":"Ann Surg"},{"issue":"10","key":"2020101314045151500_djaa012-B69","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9","article-title":"\u201cMicroscopic satellites\u201d are more highly associated with regional lymph node metastases than is primary melanoma thickness","volume":"53","author":"Harrist","year":"1984","journal-title":"Cancer"},{"issue":"12","key":"2020101314045151500_djaa012-B70","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archsurg.1991.01410360031006","article-title":"The prognostic implications of microscopic satellites in patients with clinical stage I melanoma","volume":"126","author":"Le\u00f3n","year":"1991","journal-title":"Arch Surg"},{"issue":"2","key":"2020101314045151500_djaa012-B71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2020101314045151500_djaa012-B72","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2002.08.024","article-title":"Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: Pathologic corollary of Eastern Cooperative Oncology Group Trial E1690","volume":"20","author":"Rao","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B73","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2559.2012.04279.x","article-title":"Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma","volume":"61","author":"Wilmott","year":"2012","journal-title":"Histopathology"},{"issue":"9","key":"2020101314045151500_djaa012-B74","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/PAS.0b013e3181753a8e","article-title":"Angiotropism is an independent predictor of local recurrence and in-transit metastasis in primary cutaneous melanoma","volume":"32","author":"Van Es","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"2020101314045151500_djaa012-B75","first-page":"35","volume-title":"Cutaneous Melanoma.","author":"Gershenwald","year":"2009","edition":"5th ed"},{"issue":"9","key":"2020101314045151500_djaa012-B76","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.21835","article-title":"Metastatic melanoma to lymph nodes in patients with unknown primary sites","volume":"106","author":"Cormier","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"2020101314045151500_djaa012-B77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2007.14.0285","article-title":"Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma","volume":"26","author":"Lee","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B78","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1524-4725.2010.01562.x","article-title":"Melanoma without a detectable primary site with metastases to lymph nodes","volume":"36","author":"Rutkowski","year":"2010","journal-title":"Dermatol Surg"},{"issue":"6","key":"2020101314045151500_djaa012-B79","doi-asserted-by":"crossref","first-page":"e66953","DOI":"10.1371\/journal.pone.0066953","article-title":"Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour","volume":"8","author":"Weide","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"2020101314045151500_djaa012-B80","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1245\/s10434-011-1801-5","article-title":"Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site","volume":"18","author":"Prens","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B81","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ejca.2012.09.005","article-title":"Melanoma of unknown primary origin: a population-based study in the Netherlands","volume":"49","author":"de Waal","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"2020101314045151500_djaa012-B82","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1245\/s10434-014-3679-5","article-title":"Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease","volume":"21","author":"van der Ploeg","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B83","first-page":"193","article-title":"Prognostic factors in 1,521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J Am Coll Surg"},{"issue":"22","key":"2020101314045151500_djaa012-B84","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"key":"2020101314045151500_djaa012-B85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4615-3080-0_6","article-title":"The natural history of melanoma, including the pattern of metastatic spread and the biological basis for metastases--staging of melanoma","volume":"65","author":"Warso","year":"1","journal-title":"Cancer Treat Res"},{"issue":"6","key":"2020101314045151500_djaa012-B86","first-page":"725","article-title":"Prognosis and staging in melanoma","volume":"23","author":"Garrison","year":"1996","journal-title":"Semin Oncol"},{"issue":"12","key":"2020101314045151500_djaa012-B87","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2345::AID-CNCR8>3.0.CO;2-K","article-title":"Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors","volume":"79","author":"Brand","year":"1997","journal-title":"Cancer"},{"issue":"4","key":"2020101314045151500_djaa012-B88","first-page":"759","article-title":"The shifting patterns of metastatic melanoma","volume":"20","author":"Cochran","year":"2000","journal-title":"Clin Lab Med"},{"issue":"8","key":"2020101314045151500_djaa012-B89","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"issue":"8","key":"2020101314045151500_djaa012-B90","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"2020101314045151500_djaa012-B91","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2017.03.030","article-title":"The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases","volume":"98","author":"Sperduto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2020101314045151500_djaa012-B92","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11060-017-2591-9","article-title":"Metastatic melanoma: prognostic factors and survival in patients with brain metastases","volume":"135","author":"Frinton","year":"2017","journal-title":"J Neurooncol"},{"issue":"5","key":"2020101314045151500_djaa012-B93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020101314045151500_djaa012-B94","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B95","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/1097-0142(20010315)91:6<1148::AID-CNCR1111>3.0.CO;2-#","article-title":"Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials","volume":"91","author":"Unger","year":"2001","journal-title":"Cancer"},{"issue":"26","key":"2020101314045151500_djaa012-B96","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"9829","key":"2020101314045151500_djaa012-B97","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"2020101314045151500_djaa012-B98","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"9839","key":"2020101314045151500_djaa012-B99","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"2020101314045151500_djaa012-B100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"2020101314045151500_djaa012-B101","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2020101314045151500_djaa012-B102","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"issue":"26","key":"2020101314045151500_djaa012-B103","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2020101314045151500_djaa012-B104","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020101314045151500_djaa012-B105","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/annonc\/mdy185","article-title":"Advances in the systemic treatment of melanoma brain metastases","volume":"29","author":"Glitza Oliva","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"2020101314045151500_djaa012-B106","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V","article-title":"Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis","volume":"72","author":"Sirott","year":"1993","journal-title":"Cancer"},{"issue":"5","key":"2020101314045151500_djaa012-B107","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2020101314045151500_djaa012-B108","doi-asserted-by":"crossref","first-page":"S664","DOI":"10.1016\/S0959-8049(16)31822-6","article-title":"Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)","volume":"51(Supp 3","author":"Larkin","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"2020101314045151500_djaa012-B109","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020101314045151500_djaa012-B110","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/cncr.29586","article-title":"Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors","volume":"121","author":"Menzies","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"2020101314045151500_djaa012-B111","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/07357900802027073","article-title":"Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma","volume":"26","author":"Bedikian","year":"2008","journal-title":"Cancer Invest"},{"issue":"11","key":"2020101314045151500_djaa012-B112","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0959-8049(02)00123-5","article-title":"Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin","volume":"38","author":"Keilholz","year":"2002","journal-title":"Eur J Cancer"},{"key":"2020101314045151500_djaa012-B113","first-page":"325","volume-title":"AJCC Cancer Staging Manual","author":"Balch","year":"2009","edition":"7th ed"},{"issue":"22","key":"2020101314045151500_djaa012-B114","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020101314045151500_djaa012-B115","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020101314045151500_djaa012-B116","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"issue":"9","key":"2020101314045151500_djaa012-B117","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"issue":"25","key":"2020101314045151500_djaa012-B118","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020101314045151500_djaa012-B119","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"issue":"23","key":"2020101314045151500_djaa012-B120","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2011.40.3519","article-title":"Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline","volume":"30","author":"Wong","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B121","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020101314045151500_djaa012-B122","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1245\/s10434-012-2562-5","article-title":"The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas","volume":"19","author":"Gershenwald","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2020101314045151500_djaa012-B123","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann Surg"},{"issue":"3","key":"2020101314045151500_djaa012-B124","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1610-0387.2007.06569.x","article-title":"Sentinel lymph node status is the most important prognostic factor for thick (&gt; or = 4 mm) melanomas","volume":"6","author":"Gutzmer","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"issue":"13","key":"2020101314045151500_djaa012-B125","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2020101314045151500_djaa012-B126","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"issue":"29","key":"2020101314045151500_djaa012-B127","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2010.30.9567","article-title":"Non-sentinel node risk score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes","volume":"28","author":"Murali","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020101314045151500_djaa012-B128","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1200\/JCO.2007.15.4179","article-title":"Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma","volume":"26","author":"Gershenwald","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020101314045151500_djaa012-B129","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"2020101314045151500_djaa012-B130","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer","volume":"27","author":"Bottomley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020101314045151500_djaa012-B131","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.ejca.2011.11.019","article-title":"Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b","volume":"48","author":"Brandberg","year":"2012","journal-title":"Eur J Cancer"},{"issue":"5","key":"2020101314045151500_djaa012-B132","first-page":"1311","article-title":"Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data","volume":"20","author":"Kilbridge","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020101314045151500_djaa012-B133","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020101314045151500_djaa012-B134","article-title":"Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600\u2013mutant melanoma","volume":"37(suppl","author":"Liszkay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"2020101314045151500_djaa012-B135","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2020101314045151500_djaa012-B136","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"116","key":"2020101314045151500_djaa012-B137","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"2020101314045151500_djaa012-B138","article-title":"A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy","volume":"37(suppl","author":"Owen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020101314045151500_djaa012-B139","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"10","key":"2020101314045151500_djaa012-B140","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020101314045151500_djaa012-B141","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"35","key":"2020101314045151500_djaa012-B142","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B143","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/1097-0142(197811)42:5<2206::AID-CNCR2820420518>3.0.CO;2-S","article-title":"Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study","volume":"42","author":"Creagan","year":"1978","journal-title":"Cancer"},{"issue":"1","key":"2020101314045151500_djaa012-B144","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijrobp.2005.06.030","article-title":"Combined-modality therapy for patients with regional nodal metastases from melanoma","volume":"64","author":"Ballo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"2020101314045151500_djaa012-B145","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1002\/cncr.24627","article-title":"The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma","volume":"115","author":"Agrawal","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2020101314045151500_djaa012-B146","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(09)70043-9","article-title":"Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma","volume":"10","author":"Guadagnolo","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B147","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0960-7404(92)90033-H","article-title":"Loco-regional nodal relapse in melanoma","volume":"1","author":"Miller","year":"1992","journal-title":"Surg Oncol"},{"issue":"1","key":"2020101314045151500_djaa012-B148","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jso.2930540107","article-title":"Local control following therapeutic nodal dissection for melanoma","volume":"54","author":"Monsour","year":"1993","journal-title":"J Surg Oncol"},{"issue":"2","key":"2020101314045151500_djaa012-B149","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0360-3016(99)00431-9","article-title":"Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy","volume":"46","author":"Lee","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2020101314045151500_djaa012-B150","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF02725332","article-title":"Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas?","volume":"7","author":"Shen","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B151","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2008.06.1910","article-title":"Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma","volume":"73","author":"Beadle","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2020101314045151500_djaa012-B152","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","article-title":"Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial","volume":"13","author":"Burmeister","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020101314045151500_djaa012-B153","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B154","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejso.2016.07.001","article-title":"(Neo)adjuvant systemic therapy for melanoma","volume":"43","author":"van Zeijl","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"2020101314045151500_djaa012-B155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2020101314045151500_djaa012-B156","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B157","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020101314045151500_djaa012-B158","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"Von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9938","key":"2020101314045151500_djaa012-B159","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"2020101314045151500_djaa012-B160","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2020101314045151500_djaa012-B161","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1200\/JOP.2016.014225","article-title":"Multidisciplinary care of laryngeal cancer","volume":"12","author":"Salvador-Coloma","year":"2016","journal-title":"J Oncol Pract"},{"issue":"9","key":"2020101314045151500_djaa012-B162","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-017-0898-1","article-title":"Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials","volume":"34","author":"Franco","year":"2017","journal-title":"Med Oncol"},{"issue":"8","key":"2020101314045151500_djaa012-B164","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1245\/s10434-017-5827-1","article-title":"Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma","volume":"24","author":"Anderegg","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B165","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/SLA.0000000000002240","article-title":"Impact of surgical approach on long-term survival in esophageal adenocarcinoma patients with or without neoadjuvant chemoradiotherapy","volume":"267","author":"Noordman","year":"2018","journal-title":"Ann Surg"},{"issue":"22","key":"2020101314045151500_djaa012-B166","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2020101314045151500_djaa012-B167","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2009.25.8541","article-title":"Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study","volume":"28","author":"Fern\u00e1ndez-Martos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020101314045151500_djaa012-B168","doi-asserted-by":"crossref","first-page":"513","DOI":"10.6004\/jnccn.2014.0056","article-title":"Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer","volume":"12","author":"Cercek","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2020101314045151500_djaa012-B169","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00008390-199812000-00010","article-title":"Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases","volume":"8","author":"Buzaid","year":"1998","journal-title":"Melanoma Res"},{"issue":"8","key":"2020101314045151500_djaa012-B170","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"2020101314045151500_djaa012-B171","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/2159-8290.CD-16-1109","article-title":"Making the most of cancer surgery with neoadjuvant immunotherapy","volume":"6","author":"Melero","year":"2016","journal-title":"Cancer Discov"},{"issue":"3","key":"2020101314045151500_djaa012-B172","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clindermatol.2012.08.012","article-title":"Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach","volume":"31","author":"Davar","year":"2013","journal-title":"Clin Dermatol"},{"issue":"12","key":"2020101314045151500_djaa012-B173","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2020101314045151500_djaa012-B174","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"2020101314045151500_djaa012-B175","first-page":"1","article-title":"Neoadjuvant dabrafenib combined with trametinib for single-centre, phase 2 trial","volume":"2045","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"2020101314045151500_djaa012-B176","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"2020101314045151500_djaa012-B177","author":"Blank"},{"issue":"11","key":"2020101314045151500_djaa012-B178","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"2020101314045151500_djaa012-B179","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"37(suppl","author":"Menzies","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020101314045151500_djaa012-B180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/bjs.11168","article-title":"Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma","volume":"106","author":"Schermers","year":"2019","journal-title":"Br J Surg"},{"issue":"7","key":"2020101314045151500_djaa012-B181","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020101314045151500_djaa012-B182","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020101314045151500_djaa012-B183","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"2020101314045151500_djaa012-B184","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1470-2045(18)30952-5","article-title":"Modulating the microbiome to improve therapeutic response in cancer","volume":"20","author":"McQuade","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaa012\/33376251\/djaa012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/9\/875\/33878539\/djaa012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/9\/875\/33878539\/djaa012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T20:22:03Z","timestamp":1602620523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/112\/9\/875\/5736552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":184,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,2,15]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaa012","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,2,15]]}}}